Roche's £90,000 Kadcyla price tag too high
This article was originally published in Scrip
Executive Summary
Roche's breast cancer dug Kadcyla (trastuzumab emtansine) is too expensive for general use on the UK's National Health Service, says NICE chief executive Sir Andrew Dillon.